Ascentage Pharma Group International (AAPG) Non-Current Deferred Tax Liability (2023 - 2024)

Ascentage Pharma Group International's Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $1.8 million for Q4 2025.

• In Q4 2025, Non-Current Deferred Tax Liability rose 7.43% year-over-year to $1.8 million; the TTM figure through Dec 2025 stood at $1.8 million (up 7.43% YoY), while the FY2025 annual figure was $1.8 million, up 10.76% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2025 stood at $1.8 million, up from $1.7 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $2.5 million in Q4 2022, with the low at $1.7 million in Q4 2024.
• The 4-year median for Non-Current Deferred Tax Liability is $2.0 million (2025), against an average of $2.0 million.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability declined 24.14% in 2024, then gained 7.43% in 2025.
• Ascentage Pharma Group International's Non-Current Deferred Tax Liability stood at $2.5 million in 2022, then fell by 9.79% to $2.2 million in 2023, then slipped by 24.14% to $1.7 million in 2024, then increased by 7.43% to $1.8 million in 2025.
• Business Quant data shows AAPG's Non-Current Deferred Tax Liability at $1.8 million in Q4 2025, $1.7 million in Q4 2024, and $2.2 million in Q4 2023.